GSK's shares have experienced volatility recently, primarily due to a FDA panel rejecting the company's blood cancer drug,
Blenrep, which had caused significant drops in its stock. In light of this, the company's shares weigh on the Footsie. However, it hasn't been all negative for GSK. The company has been on an aggressive stock buyback program to enhance shareholder value. GSK's
shingles vaccine innovation also gained FDA approval, providing the company new opportunities to dominate in Senior Healthcare. Furthermore, GSK’s
Specialty Medicines Unit shows strong footing and the prefilled shingles vaccine,
Shingrix, has gained FDA approval. The directors of the company are also increasing their stake, signalling their confidence in the future of the company. The undervaluation of the company makes it an attractive investment as deemed by many analysts. The company is also deemed to be well positioned to manoeuvre tariffs. Lastly, GSK has announced total voting rights and capital update.
GSK Stocks News Analytics from Wed, 05 Feb 2025 08:00:00 GMT to Sun, 20 Jul 2025 00:40:26 GMT -
Rating -2
- Innovation 1
- Information 5
- Rumor -5
